Stay informed with our
free newsletters

Jubilant HollisterStier Announces $92M Expansion

Fueled by COVID drug manufacturing revenues, CDMO Jubilant HollisterStier invests in upgrades, expansion

Jubilant HollisterStier, a wholly owned subsidiary of ultimate parent company Jubilant Pharmova Limited, announces $92M investment to expand sterile injectable manufacturing capacity at its site in Spokane, WA. This investment is being made to set up a high-speed 400 vials a minute injectable fill line with isolator technology, which will enhance the Spokane facility’s capacity by 50%. This expansion will also include two 300 sq. foot lyophilizers. This expansion will be spread over 50,000 sq. feet at the Spokane facility and will be commercially operational by the end of 2024. Jubilant HollisterStier has already begun filling new roles to support this expansion and will continue to recruit additional talent.

“We are excited to expand our sterile injectable and vaccine manufacturing capacity and meet the increasing demand from our customers.” said Amit Arora, President Jubilant HollisterStier.

“We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response. This expansion will also help us meet high demand from our global Specialty Pharmaceutical customers, with whom the company has established strong relationships” stated Pramod Yadav, CEO Jubilant Pharma Limited.

mRNA: Therapeutics and Global Markets

mRNA: Therapeutics and Global Markets

Download free sample pages

Source: Jubilant HollisterStier
Date: Jun 3, 2021


Share this news: